Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a Patient's own kidney cells hold off dialysis?

NCT ID NCT06790498

Disease control Sponsor: Prokidney Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 17, 2026 · Last updated Sep 18, 2026 · Updated 1 time

Summary

Researchers are following people with chronic kidney disease who received up to four injections of REACT, a therapy made from their own kidney cells, in earlier studies. The goal is to track long-term safety and see how long any effects on kidney function last. About 50 participants who already had REACT will be monitored for delayed side effects and for signs such as when kidney function drops or dialysis becomes necessary.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Renal Autologous Cell Therapy (REACT), a cell therapy made from a patient's own kidney cells and injected into the kidney
What this could lead to
If the therapy holds up over time, it could offer a way to slow kidney decline in people with diabetic kidney disease and chronic kidney disease.
What could go wrong
This is a follow-up study of a small group, so it cannot prove the therapy works. Delayed side effects may appear, and any benefits seen earlier may fade.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2023

Expected to finish

Aug 2030

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with Chronic Kidney Disease

Ages

30 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * The participant must have received REACT in a previous trial (REGEN-006, REGEN- 007, and REGEN-015) for the treatment of chronic kidney disease and completed an end of study visit in their previous trial per protocol. * The participant is willing and able to cooperate with all aspects of the protocol. * The participant is willing and able to provide signed informed consent. Exclusion Criteria: • Participant did not receive REACT in a previous trial for the treatment of chronic kidney disease

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic kidney disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome diabetic kidney disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic kidney disease Diabetic kidney disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Boise Kidney & Hypertension Institute

    Meridian, Idaho, 83642, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.